top of page
The Professional Network for Healthcare Experts
European Commission approves Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
nuaxia
Sep 22 min read
EU approves Etcamah and advances Enhertu combination for biomarker-defined breast cancers
The two regulatory decisions could expand first-line treatment options for patients with ESR1-mutant ER-positive disease and HER2-positive metastatic breast cancer, although Enhertu still requires European Commission approval.
nuaxia
Jul 312 min read
bottom of page